Breathe Well Live Well
|
Glaxo's Eosinophilic Asthma Drug Nucala Wins CHMP Backing
Yahoo News Several companies including Teva Pharmaceutical Industries Limited TEVA and AstraZeneca plc AZN are looking to bring their anti IL-5 antibodies to the market for the treatment of severe asthma and chronic obstructive pulmonary disease (COPD). |
View full post on asthma – Google News
BioPharma Dive |
Glaxos Eosinophilic Asthma Drug Nucala Wins CHMP Backing
Zacks.com In the U.S., the drug is approved for both COPD and asthma. We note that Glaxo has a collaboration agreement with Theravance for Relvar/Breo Ellipta and Anoro Ellipta (COPD). Relvar/Breo Ellipta generated sales of £94 million in the first half of 2015. After bad news on Breo, Glaxo's monthly asthma drug wins an EU rec |
View full post on asthma – Google News
PMLiVE |
CHMP backs GSK's asthma antibody and Novartis' heart failure drug
PMLiVE GlaxoSmithKline's mepolizumab for severe asthma and Novartis new' heart failure therapy Entresto have been recommended for approval by the Committee for Medicinal Products for Human Use (CHMP). The panel issued positive opinions for the two drugs … |
View full post on asthma – Google News
Medscape |
CHMP Backs Mepolizumab for Severe Eosinophilic Asthma
Medscape The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has recommended approval of mepolizumab (Nucala, GlaxoSmithKline) for add-on maintenance treatment in adults with severe refractory eosinophilic asthma, … EU regulator backs approval for GSK injectable asthma drug GlaxoSmithKline's asthma injection heads for EU approval Glaxo asthma drug clears key hurdle in Europe |
View full post on asthma – Google News
|
Teva's DuoResp Spiromax gets positive CHMP opinion to treat asthma and COPD
Pharmaceutical Business Review DuoResp Spiromax is a new multi-dose dry-powder inhaler with a combination of budesonide, an inhaled corticosteroid for the treatment of underlying inflammation in asthma and COPD, and formoterol fumarate dihydrate, a rapid-acting and long-lasting … Teva's Symbicort generic backed for EU approval 10 new medicines recommended for approval in Europe |
View full post on asthma – Google News
|
Teva Gets Positive CHMP Opinion For DuoResp Spiromax To Treat Asthma And …
RTT News DuoResp Spiromax is a new multi-dose dry-powder inhaler with a combination of budesonide, an inhaled corticosteroid to treat the underlying inflammation in asthma and COPD, and formoterol fumarate dihydrate, a rapid-acting and long-lasting beta2 … EU Agency backs respiratory drugs for approval EMA Backs Generic Versions of AstraZeneca's Symbicort |
View full post on asthma – Google News
|
Teva Gets Positive CHMP Opinion For DuoResp Spiromax To Treat Asthma And …
NASDAQ DuoResp Spiromax is a new multi-dose dry-powder inhaler with a combination of budesonide, an inhaled corticosteroid to treat the underlying inflammation in asthma and COPD, and formoterol fumarate dihydrate, a rapid-acting and long-lasting beta2 … UPDATE 1-EU Agency backs respiratory drugs for approval EMA Backs Generic Versions of AstraZeneca's Symbicort |
View full post on asthma – Google News